(Esketamine) Spravato Marketing

In March of 2019, the FDA approved esketamine nasal spray for use in the treatment of depression. Esketamine, which is a derivative of ketamine, is the first new treatment for depression to be approved by the FDA in more than 30 years.

The approval of Spravato (esketamine) was based on the results of two clinical trials in which it was found to be more effective than a placebo in reducing symptoms of depression. Esketamine was also found to be well-tolerated and is a fast-acting antidepressant that can help improve your mood in as little as four days. It's a newer drug that's been shown to be more effective than traditional antidepressants, and it comes with a lower risk of side effects. 

Esketamine is thought to work by blocking NMDA receptors, which are involved in the brain's response to pain and stress. By blocking these receptors, esketamine may help to relieve the symptoms of depression.

Esketamine is approved for the treatment of adults with major depressive disorder who have not responded to other antidepressant medications. It is important to note that esketamine is not a standalone treatment for depression, but should be used in combination with other medications.

Since Spravato is a newer medication, it may not be covered by all insurance plans. That's why it's important to check with your insurance provider to see if you're eligible for coverage. If you're not covered by insurance, or if your insurance doesn't cover Spravato, there may be other payment options available to you. You can talk to your doctor about getting help paying for your medication. 

Reach out to us to discuss advertising plans for mental health and esketamine treatments at your clinic.